Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Kazakhstan has been steadily growing in recent years, driven by various factors such as an aging population and an increase in the prevalence of cardiovascular diseases.
Customer preferences: Patients in Kazakhstan are increasingly opting for newer and more advanced anti-coagulants, such as direct oral anticoagulants (DOACs), over traditional warfarin-based therapies. This is due to the convenience of DOACs, which do not require regular monitoring and have fewer interactions with other drugs and food.
Trends in the market: The Anti-Coagulants market in Kazakhstan is expected to continue growing in the coming years, driven by factors such as an increase in the prevalence of cardiovascular diseases and a growing aging population. Additionally, the government's focus on improving healthcare infrastructure and increasing access to healthcare services is expected to further fuel market growth.
Local special circumstances: Kazakhstan is the largest landlocked country in the world and has a population of over 18 million people. The country has a rapidly growing economy and is strategically located at the crossroads of Europe and Asia. However, the healthcare system in Kazakhstan is still developing and faces various challenges such as inadequate funding, a shortage of trained healthcare professionals, and limited access to healthcare services in rural areas.
Underlying macroeconomic factors: The Anti-Coagulants market in Kazakhstan is influenced by various macroeconomic factors such as the country's GDP growth, inflation rates, and government healthcare spending. The government's focus on improving healthcare infrastructure and increasing access to healthcare services is expected to have a positive impact on the market, while factors such as economic instability and political uncertainty could pose challenges to market growth. Additionally, the COVID-19 pandemic has had an impact on the market, with an increased focus on healthcare and a growing demand for anti-coagulants due to the virus's impact on blood clotting.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
